Vancouver-based Advanced Proteome Therapeutics Corp (CVE:APC) says it has signed an agreement with the Stanford University School of Medicine to test protein conjugates and multimers as part of the company's Foundation Trinity cancer treatment.
Stanford will be testing Advanced Proteome's protein modifications to determine their effects on tumors in a number of cancer disease states.
“We are extraordinarily fortunate in having Stanford’s participation in our program involving cancer therapeutics. The School of Medicine’s expertise is unrivaled in APC’s areas of interest," said Advanced Proteome's president and CEO, Dr. Allen Krantz.
Advanced Proteome has a potential three-in-one cancer treatment that acts as a targeted, combination and homogeneous therapy - all in a single agent. The company's technology is based on a proprietary platform that can be used to attach known therapeutics to specific sites on proteins - in this case, proteins that have shown affinity for specific cancer cells, hence the targeted and combination therapy.
The attachments are designed to boost the properties of the protein targeted for the specific cancer cells, giving it additional therapeutic abilities.
The homogeneity aspect of Advanced Proteome's therapy originates from the use of a protein not only as a delivery system, but also as a scaffold on which to attach each anti-cancer entity to its own specific site on the protein, and allows the company to produce single agents, or protein conjugates, bearing multiple therapies.
The news today of an agreement to test the protein conjugates follows a similar deal with the University of Iowa, inked back in late April, as part of the company's program of preclinical testing of its proprietary protein modifications.
The first round of testing of the single agents will screen for their ability to target cancer cells specifically, and for any obvious toxic effects on healthy cells.
Advanced Proteome says it also expects that any promising agents will undergo animal testing in a second round, to determine the potency and toxicity of the therapy.
Investors are indeed tuning into the company's progress and development plans, with its shares having doubled in value since the start of the year, rising 100 per cent to close on Friday at 18 cents per share, up from 8.5 cents at the beginning of January.
No comments:
Post a Comment